Adalimumab is effective in patients with preradiographic axial spondyloarthritis (PRSPA): Results of a 12-week, randomised controlled trial with a 40-week open-label extension (OLE)

被引：0
|
作者：
Haibel, H. [1 ]
Rudwaleit, M. [1 ]
Amtenbrink, A. [1 ]
Heldmann, F. [2 ]
Listing, J. [3 ]
Wong, R. [4 ]
Kupper, H. [5 ]
Braun, J. [2 ]
Sieper, J. [1 ]
机构：
[1] Charite Univ Med Berlin, D-13353 Berlin, Germany
[2] Ruhrgebeit, Herne, Germany
[3] German Rheumatism Res Ctr, Berlin, Germany
[4] Abbott, Parsippany, NJ USA
[5] Abbott GmbH & Co KG, Ludwigshafen, Germany
来源：
RHEUMATOLOGY | 2008年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：II80 / II80
页数：1
相关论文
共 50 条
  • [21] Safety results from a 12-week open-label, multicenter study of sodium oxybate in patients with narcolepsy
    Mamelak, M.
    Swick, T.
    Emsellem, H.
    Montplaisir, J.
    Lai, C.
    Black, J.
    JOURNAL OF SLEEP RESEARCH, 2014, 23 : 289 - 289
  • [22] PREDICTORS OF REMISSION AT WEEK 12 IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING OPEN-LABEL ADALIMUMAB TREATMENT IN THE ABILITY-3 STUDY
    Sieper, J.
    Landewe, R.
    Magrey, M.
    Anderson, J. K.
    Zhong, S.
    Wang, X.
    Lertratanakul, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 156 - 156
  • [23] Persistence of Effect of Dextromethorphan Hydrobromide/Quinidine Sulfate (DM/Q) for Pseudobulbar Affect (PBA): Results from a 12-Week Open-Label Extension (OLE) Study
    Brooks, Benjamin Rix
    Pioro, Erik P.
    Shin, Paul
    Law, Ryan
    Formella, Andrea E.
    NEUROLOGY, 2017, 88
  • [24] Adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 52-week trial
    Haibel, H
    Brandt, H
    Baraliakos, X
    Rudwaleit, M
    Listing, J
    Braun, J
    Kupper, H
    Sieper, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 316 - 316
  • [25] EFFICACY OF ADALIMUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INVESTIGATOR-INITIATED 12-WEEKS RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH A 12 WEEKS OPEN-LABEL EXTENSION PHASE
    Pedersen, S. J.
    Sorensen, I. J.
    Loft, A. G.
    Hindrup, J. S.
    Thamsborg, G.
    Asmussen, K.
    Kluger, E.
    Norregaard, J.
    Christensen, T. G.
    Jurik, A. G.
    Moller, J. M.
    Hasselquist, M.
    Skjodt, T.
    Mikkelsen, D.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 289 - 289
  • [26] A 12-Week, Open-Label Study Evaluating Sodium Oxybate (SXB) in Patients with Narcolepsy
    Mamelak, Mortimer
    Swick, Todd
    Emsellem, Helene
    Montplaisir, Jacques
    Lai, Chinglin
    Black, Jed
    ANNALS OF NEUROLOGY, 2014, 76 : S131 - S132
  • [27] Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial
    Peris, K
    Campione, E
    Micantonio, T
    Marulli, GC
    Fargnoli, MC
    Chimenti, S
    DERMATOLOGIC SURGERY, 2005, 31 (03) : 318 - 323
  • [28] Aripiprazole therapy in 20 older adults with bipolar disorder: A 12-week, open-label trial
    Sajatovic, Martha
    Coconcea, Nicoleta
    Ignacio, Rosalinda V.
    Blow, Frederic C.
    Hays, Robert W.
    Cassidy, Kristin A.
    Meyer, William J.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 41 - 46
  • [29] Effects of bupropion on depression of Parkinson's disease: Open-label 12-week trial in Korea
    Kim, W. C.
    Kim, H. S.
    Oh, S. H.
    Kim, O. J.
    Lee, M. S.
    MOVEMENT DISORDERS, 2009, 24 : S241 - S241
  • [30] Modafinil as augmentation of SSRI monotherapy in major depressive disorder: A 12-week, open-label extension study
    Thase, ME
    Fava, M
    DeBattista, C
    Fannelli, J
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S238 - S238
12345